BPC-157 and TB-500 under FDA review: why regenerative peptide research is entering a new era
BPC-157 and TB-500 are scheduled for FDA advisory committee discussion on July 23, 2026 (evaluated uses: ulcerative colitis and wound healing). What it means for regenerative peptide research, compounding policy and research-use standards - and why a review is not an approval.